Non-Hodgkin's lymphomas in the elderly: Prospective studies with specifically devised chemotherapy regimens in 66 patients

Umberto Tirelli, Antonino Carbone, Vittorina Zagonel, Andrea Veronesi, Renzo Canetta

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The results of 2 consecutive and prospective trials with specifically devised chemotherapy regimens in elderly patients (pts) with non-Hodgkin's lymphoma (NHL) are reported. Between August 1979 and September 1984, 66 pts aged 70 or older (median 75 years) with NHL entered 2 consecutive trials, the former with single agent teniposide 100 mg/m2 i.v. weekly (41 pts), the latter with etoposide and prednimustine (E + P), 100 mg/m p.o. for 5 days every 21 days (25 pts). Forty-five pts were previously untreated, 21 previously treated. Forty-seven pts were of the intermediate and high grade groups according to the Working Formulation; 19 pts were of the low grade; 57 pts were stages III and IV, 9 pts were stages I and II. The median performance status was 70 (range 30-100). The objective response rate in the 66 evaluable pts is 53% with 38% CR; the 3-year overall, disease-free and CR survivals are 21, 12 and 40% respectively. The objective response rate in the 45 previously untreated pts is 58% with 42% CR; the 3-year overall, disease-free and CR survivals are 24, 16 and 58% respectively. The overall toxicity was mild. Severe toxicity (grade III and IV according to WHO criteria) was observed only in 16 498 courses (3.2%), with 1 toxic death (grade IV leucopenia). We experienced the usefulness of a properly oriented clinical approach to elderly pts with NHL. We suggest that a combination regimen like E + P, suitable for oral administration, may be safely employed in a large fraction of pts with NHL.

Original languageEnglish
Pages (from-to)535-540
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number5
DOIs
Publication statusPublished - 1987

Fingerprint

Non-Hodgkin's Lymphoma
Prospective Studies
Drug Therapy
Disease-Free Survival
Prednimustine
Teniposide
Poisons
Leukopenia
Etoposide
Oral Administration

ASJC Scopus subject areas

  • Oncology

Cite this

Non-Hodgkin's lymphomas in the elderly : Prospective studies with specifically devised chemotherapy regimens in 66 patients. / Tirelli, Umberto; Carbone, Antonino; Zagonel, Vittorina; Veronesi, Andrea; Canetta, Renzo.

In: European Journal of Cancer and Clinical Oncology, Vol. 23, No. 5, 1987, p. 535-540.

Research output: Contribution to journalArticle

@article{423e0e931cf34ff88a325b0fec9f86b9,
title = "Non-Hodgkin's lymphomas in the elderly: Prospective studies with specifically devised chemotherapy regimens in 66 patients",
abstract = "The results of 2 consecutive and prospective trials with specifically devised chemotherapy regimens in elderly patients (pts) with non-Hodgkin's lymphoma (NHL) are reported. Between August 1979 and September 1984, 66 pts aged 70 or older (median 75 years) with NHL entered 2 consecutive trials, the former with single agent teniposide 100 mg/m2 i.v. weekly (41 pts), the latter with etoposide and prednimustine (E + P), 100 mg/m p.o. for 5 days every 21 days (25 pts). Forty-five pts were previously untreated, 21 previously treated. Forty-seven pts were of the intermediate and high grade groups according to the Working Formulation; 19 pts were of the low grade; 57 pts were stages III and IV, 9 pts were stages I and II. The median performance status was 70 (range 30-100). The objective response rate in the 66 evaluable pts is 53{\%} with 38{\%} CR; the 3-year overall, disease-free and CR survivals are 21, 12 and 40{\%} respectively. The objective response rate in the 45 previously untreated pts is 58{\%} with 42{\%} CR; the 3-year overall, disease-free and CR survivals are 24, 16 and 58{\%} respectively. The overall toxicity was mild. Severe toxicity (grade III and IV according to WHO criteria) was observed only in 16 498 courses (3.2{\%}), with 1 toxic death (grade IV leucopenia). We experienced the usefulness of a properly oriented clinical approach to elderly pts with NHL. We suggest that a combination regimen like E + P, suitable for oral administration, may be safely employed in a large fraction of pts with NHL.",
author = "Umberto Tirelli and Antonino Carbone and Vittorina Zagonel and Andrea Veronesi and Renzo Canetta",
year = "1987",
doi = "10.1016/0277-5379(87)90316-6",
language = "English",
volume = "23",
pages = "535--540",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Non-Hodgkin's lymphomas in the elderly

T2 - Prospective studies with specifically devised chemotherapy regimens in 66 patients

AU - Tirelli, Umberto

AU - Carbone, Antonino

AU - Zagonel, Vittorina

AU - Veronesi, Andrea

AU - Canetta, Renzo

PY - 1987

Y1 - 1987

N2 - The results of 2 consecutive and prospective trials with specifically devised chemotherapy regimens in elderly patients (pts) with non-Hodgkin's lymphoma (NHL) are reported. Between August 1979 and September 1984, 66 pts aged 70 or older (median 75 years) with NHL entered 2 consecutive trials, the former with single agent teniposide 100 mg/m2 i.v. weekly (41 pts), the latter with etoposide and prednimustine (E + P), 100 mg/m p.o. for 5 days every 21 days (25 pts). Forty-five pts were previously untreated, 21 previously treated. Forty-seven pts were of the intermediate and high grade groups according to the Working Formulation; 19 pts were of the low grade; 57 pts were stages III and IV, 9 pts were stages I and II. The median performance status was 70 (range 30-100). The objective response rate in the 66 evaluable pts is 53% with 38% CR; the 3-year overall, disease-free and CR survivals are 21, 12 and 40% respectively. The objective response rate in the 45 previously untreated pts is 58% with 42% CR; the 3-year overall, disease-free and CR survivals are 24, 16 and 58% respectively. The overall toxicity was mild. Severe toxicity (grade III and IV according to WHO criteria) was observed only in 16 498 courses (3.2%), with 1 toxic death (grade IV leucopenia). We experienced the usefulness of a properly oriented clinical approach to elderly pts with NHL. We suggest that a combination regimen like E + P, suitable for oral administration, may be safely employed in a large fraction of pts with NHL.

AB - The results of 2 consecutive and prospective trials with specifically devised chemotherapy regimens in elderly patients (pts) with non-Hodgkin's lymphoma (NHL) are reported. Between August 1979 and September 1984, 66 pts aged 70 or older (median 75 years) with NHL entered 2 consecutive trials, the former with single agent teniposide 100 mg/m2 i.v. weekly (41 pts), the latter with etoposide and prednimustine (E + P), 100 mg/m p.o. for 5 days every 21 days (25 pts). Forty-five pts were previously untreated, 21 previously treated. Forty-seven pts were of the intermediate and high grade groups according to the Working Formulation; 19 pts were of the low grade; 57 pts were stages III and IV, 9 pts were stages I and II. The median performance status was 70 (range 30-100). The objective response rate in the 66 evaluable pts is 53% with 38% CR; the 3-year overall, disease-free and CR survivals are 21, 12 and 40% respectively. The objective response rate in the 45 previously untreated pts is 58% with 42% CR; the 3-year overall, disease-free and CR survivals are 24, 16 and 58% respectively. The overall toxicity was mild. Severe toxicity (grade III and IV according to WHO criteria) was observed only in 16 498 courses (3.2%), with 1 toxic death (grade IV leucopenia). We experienced the usefulness of a properly oriented clinical approach to elderly pts with NHL. We suggest that a combination regimen like E + P, suitable for oral administration, may be safely employed in a large fraction of pts with NHL.

UR - http://www.scopus.com/inward/record.url?scp=0023091988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023091988&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(87)90316-6

DO - 10.1016/0277-5379(87)90316-6

M3 - Article

C2 - 3653177

AN - SCOPUS:0023091988

VL - 23

SP - 535

EP - 540

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -